Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Dr. Bina Naik and Dr. Ashish Indani
PharmaShots Interview: Impact of new regulations and trends in the medical device industry in India – interviews of Dr. Bina Naik and Dr. Ashish Indani during DIA Medical Device Conference 20
The Medical Devices Conference was hosted by DIA India on 21st and 22nd February in collaboration with the Medical Technology Association of India (MTaI), AIC-AMTZ Medivalley Incubation Council and mDI Europa, is one of the largest gatherings of medical devices professionals in the region. The conference was focused on giving better insights into the challenges…
June 22, 2021
Viewpoints_Thomas Slavin
PharmaShots Interview: Myriad Genetics’ Thomas Slavin Shares Insights on the Data Validating Breast Cancer PRS Across Ancestries
In an interview with PharmaShots, Dr. Thomas Slavin, M.D, Senior Vice President of Medical Affairs, Oncology at Myriad Genetics and study co-author shared his views on the data presented at ASCO 2021 and its implications for women. Shots: Myriad Genetics data helps more women to control their health by helping them understand their lifetime risk of developing…
June 22, 2021
Viewpoints_Dr. Bob Deans
PharmaShots Interview: Synthego’s Dr. Bob Deans Shares Insights on the Launch of its Eclipse Platform for Drug Discovery
In an interview with PharmaShots, Dr. Bob Deans, Chief Scientific Officer at Synthego shares insights on the wide availability of its new CRISPR-based platform, Eclipse. Synthego created the Eclipse platform to enhance disease modeling, drug target identification, and validation, and accelerate cell therapy manufacturing. Shots: Eclipse uses MLto apply experience from several hundred thousand genome edits across…
June 22, 2021
Viewpoints_Dr. Stanley T. Crooke
PharmaShots Interview: n-Lorem Foundation’s Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients
In an interview with PharmaShots, Dr. Stanley T. Crooke, Founder, and Chief Executive Officer and Chairman of the Board at n-Lorem Foundation share his views on the collaboration with Ultragenyx. Shots: n-Lorem Foundation is the first & only foundation of its kind with a mission to provide life-saving treatments to patients who have diseases caused by extremely rare…
June 15, 2021
Viewpoints_Dr. Maria Ines Mitrani
PharmaShots Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19
In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. Shots: This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, which has entered into a product testing and distribution agreement with Organicell…
June 15, 2021
Viewpoints_Dr. Malcolm Barratt-Johnson
PharmaShots Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies
In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic therapies, the company's business model, and your plans for scaling the psychedelics therapies. Shots: Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access to patients…
June 11, 2021
Viewpoints_Mike Crichton
PharmaShots Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe
In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission's approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). Shots: The European Commission approved the expanded use of GSK's…
June 8, 2021
Viewpoints_Dr. Gill Diamond and Joshua McClure
PharmaShots Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2
In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2. Shots: The studies showed that antiviral peptoids…
June 7, 2021
Load more